Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $15.32, but opened at $14.90. Dr. Reddy's Laboratories shares last traded at $14.87, with a volume of 96,325 shares.
Analyst Upgrades and Downgrades
RDY has been the topic of several research analyst reports. Barclays reduced their price target on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. StockNews.com downgraded Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th. Finally, Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.
Get Our Latest Analysis on RDY
Dr. Reddy's Laboratories Stock Performance
The stock's 50-day moving average price is $14.86 and its 200-day moving average price is $15.55. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $12.44 billion, a P/E ratio of 23.82 and a beta of 0.51.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Lifestyle Asset Management Inc. grew its position in shares of Dr. Reddy's Laboratories by 422.2% during the fourth quarter. Lifestyle Asset Management Inc. now owns 71,488 shares of the company's stock worth $1,129,000 after acquiring an additional 57,799 shares during the last quarter. SG Americas Securities LLC bought a new position in Dr. Reddy's Laboratories in the 4th quarter worth about $145,000. Simon Quick Advisors LLC bought a new stake in shares of Dr. Reddy's Laboratories during the fourth quarter valued at approximately $224,000. Atomi Financial Group Inc. acquired a new position in shares of Dr. Reddy's Laboratories during the fourth quarter worth approximately $162,000. Finally, Crossmark Global Holdings Inc. grew its holdings in Dr. Reddy's Laboratories by 328.3% in the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock worth $201,000 after buying an additional 9,781 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Read More
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
